Diabetes for surgeons. Dr. Maria Wolfs Assistant Professor Endocrinology and Metabolism St. Michael s Hospital

Size: px
Start display at page:

Download "Diabetes for surgeons. Dr. Maria Wolfs Assistant Professor Endocrinology and Metabolism St. Michael s Hospital"

Transcription

1 Diabetes for surgeons Dr. Maria Wolfs Assistant Professor Endocrinology and Metabolism St. Michael s Hospital

2 Outline Background and evidence Approach to the perioperative patient with DM The patient The treatment The surgery Case discussions

3 DM in hospitalized patients Approximately 1 in 4 patients admitted to the hospital has a known diagnosis of diabetes 30% of patients with diabetes require >2 hospitalizations in any given year High prevalence of diabetes elderly patients residents of long-term-care facilities up to one third of adults aged yr 40% of those older than 80 yr Umpierrez, GE et al. JCEM 2012;97:16-38

4 Perioperative hyperglycemia Case control studies increased risk for adverse outcomes in patients undergoing elective noncardiac surgery BG values > 11.1 mmol/l associated with prolonged hospital length of stay increased risk of postoperative complications wound infections and cardiac arrhythmias Umpierrez, GE et al. JCEM 2012;97:16-38

5 Perioperative hyperglycemia postoperative infections 2.7 times higher in patients with glucose > 12.2 mmol/liter than in those with glucose levels below 12.2 mmol/liter 3184 noncardiac general surgery patients perioperative glucose value above 8.3 mmol/liter associated with increased length of stay, hospital complications, and postoperative mortality Umpierrez, GE et al. JCEM 2012;97:16-38

6 Reduced risk of infection Infection RR 0.41 ( ) Murad, MH et al. JCEM 2012;97:49

7 Glycemic targets in hospital non-critically ill patients treated with insulin premeal glucose of < 7.8 mmol/l random BG of <10.0 mmol/liter avoid hypoglycemia (<3.9 mmol/liter) insulin dose should be reduced if glucose levels are between 3.9 mmol/liter and 5.6 mmol/l higher glucose ranges BG < 11.1 mmol/liter terminally ill patients patients with severe comorbidities Umpierrez, GE et al. JCEM 2012;97:16-38

8 Glycemic targets in hospital Provided that their medical conditions, dietary intake and glycemic control are acceptable, patients with diabetes should be maintained on their prehospitalization oral antihyperglycemic agents or insulin regimens [Grade D, Consensus]. Perioperative glycemic levels should be maintained between 5.0 and 11.0 mmol/l for most other surgical situations, with an appropriate protocol and trained staff to ensure the safe and effective implementation of this therapy and minimize the likelihood of hypoglycemia [Grade D, Consensus]. CDA 2008 Clinical Practice Guidelines

9 Outline Background and evidence Approach to the perioperative patient with DM The patient The treatment The surgery Case discussions

10 Case #1 52F scheduled for TAH tomorrow am Type 2 DM x 6 years, obesity Medications Metformin 1000mg bid Gliclazide MR 60mg am Humulin N 20u hs Atorvastatin 10mg hs Perindopril 8mg

11 Case #2 29M MVC multiple fractures and head injury Type 1 DM since age 4 Medications Humalog Lantus 12 units hs On call to OR

12 Case #3 75M POD2 bowel obstruction Type 2 DM x 10 years A1c 7.6% Medications at home Metformin 1000mg bid Gliclazide MR 120mg Sitagliptin 100mg

13 Case #4 58F scheduled for total thyroidectomy for multinodular goitre Type 2 DM for 10 years A1c 7.3% Metformin 1g bid Humulin Mix

14 Case #5 78M POD 5 hip fracture ORIF Type 2 diabetes Metformin 1000mg BID Glyburide 10mg BID Continuous NG feeds - swallowing concerns BS on oral meds mmol/l

15 Approach to perioperative DM The Patient The Treatment The Surgery

16 The Patient Type 1 or Type 2 Type 1 need insulin at all times!!! Glycemic control A1c, SMBG Diet NPO, DAT, clear fluids, NG feeds, TPN Activity level Medications Steroids Organ dysfunction/failure Ischemia

17 The Treatment Oral agents Insulin Both Basal coverage Correction factor

18 Oral anti-hyperglycemic drugs Class Agents Concern Stop if: Biguanides Metformin Lactic acidosis CHF, renal insufficiency (egfr <30ml/min), hypoperfusion, or chronic pulmonary disease, at risk of developing renal failure and lactic acidosis, iv contrast dye Sulfonylurea Gliclazide (Diamicron) Glyburide (Diabeta) Glimeperide (Amaryl) Repaglinide (Gluconorm) Nataglinide (Starlix) Hypoglycemia (Elderly, impaired renal function, poor nutritional intake) Hypoglycemia NPO, reduce dose if diet reduced NPO

19 Oral anti-hyperglycemic drugs Class Agents Concern Stop if: DPPIV Inhibitors Thiazolidined iones (TZD) Alphaglucosidase inhibitor Sitagliptin (Januvia) Saxagliptin (Onglyza) Linagliptin (Trajenta ) Pioglitazone (Actos) Rosiglitazone (Avandia) Renal impairment: Sita egfr <50 Saxa 2.5mg if egrf Lina approved in ESRD Causes CHF Rosi increased CV mortality Bladder CA Atypical fractures NPO CHF CAD Liver failure Acarbose GI upset NPO

20 Insulin 101 TDD = total daily dose of insulin BASAL insulin = 40% of TDD BOLUS insulin = 60% TDD BOLUS 60% BASAL 40%

21 Insulin 101 TDD = total daily dose of insulin BASAL insulin = 40% of TDD BOLUS insulin = 60% TDD

22 Insulin 101 TDD = total daily dose of insulin BASAL insulin = 40% of TDD BOLUS insulin = 60% TDD Basal coverage Correction factor

23 Insulin 101 BOLUS 60% BASAL 40%

24 Insulin pharmacokinetics BOLUS BASAL MIXED PUMP Humulin Novolin Sanofi Onset (h) Peak (h) Duration (h) Humalog Regular N - - Humalog Mix 25 Humulin 30/70 Novorapid Toronto NPH Levemir - Novomix 30 Novolin 30/70 Apidra Lantus Basal coverage Correction factor

25 Insulin pharmacokinetics BOLUS BASAL MIXED PUMP Humulin Novolin Sanofi Onset (h) Peak (h) Duration (h) Humalog Regular N - - Humalog Mix 25 Humulin 30/70 Novorapid Toronto NPH Levemir - Novomix 30 Novolin 30/70 Apidra Lantus

26 Ensuring basal coverage Day surgery with anticipated eating soon Usual DM regimen Oral agents only Oral agents + bedtime N Oral agents + bedtime Lantus or Levemir Mixed insulin BID MDI with bedtime N MDI with am and bedtime N MDI with Lantus or Levemir Insulin pump Basal coverage for AM of surgery Hold until eating Usual dose of bedtime N Usual dose of bedtime Lantus or Levemir 20% of TDD as morning N Usual dose of bedtime N 70% of am N Continue usual dose of Lantus or Levemir Continue basal rate

27 Basal insulin Humulin Novolin Sanofi Onset (h) Peak (h) Duration (h) BASAL N - - NPH Levemir Lantus Subcutaneous N/NPH 40% AM 60% HS 25% q6h 33% q8h Levemir/Lantus 100% HS Intravenous drip

28 Basal insulin = 40% TDD Home regimen TDD Basal (40% TDD) Oral agents only Oral agents + bedtime insulin Mixed insulin BID MDI Unknown starting dose Assume 30 units/day Assume 50 units/day Calculate daily dose e.g = units/day Calculate daily dose e.g. Humalog Humulin N = units/day Estimate based on weight (kg) Type 1 kg x 0.3 units/kg/day Type 2 kg x 0.5 units/kg/day e.g. 60 kg woman Type 1 units/day e.g. 100 kg man Type 2 units/day

29 Basal insulin = 40% TDD Home regimen TDD Basal (40% TDD) Oral agents only Assume 30 units/day 12 Oral agents + bedtime insulin Mixed insulin BID MDI Unknown starting dose Assume 50 units/day 20 Calculate daily dose e.g = 60 units/day Calculate daily dose e.g. Humalog Humulin N = 100 units/day Estimate based on weight (kg) Type 1 kg x 0.3 units/kg/day Type 2 kg x 0.5 units/kg/day e.g. 60 kg woman Type 1 18 units/day e.g. 100 kg man Type 2 50 units/day

30 IV insulin infusion Check for institution s pre-printed order set 1. Order insulin concentration 50 units of Humulin R in 500cc D5W 1 unit = 10 cc

31 IV insulin infusion Check for institution s pre-printed order set 1. Order insulin concentration 50 units of Humulin R in 500cc D5W 1 unit = 10 cc 2. Order IV fluids Glucose containing (D5W, ⅔:⅓)

32 IV insulin infusion Check for institution s pre-printed order set 1. Order insulin concentration 50 units of Humulin R in 500cc D5W 1 unit = 10 cc 2. Order IV fluids Glucose containing (D5W, ⅔:⅓) 3. Calculate basal rate

33 Insulin 101 basal insulin IV insulin drip rate = daily basal/24 hours Home regimen TDD Basal IV insulin drip Oral agents only Oral agents + bedtime insulin Mixed insulin BID MDI Unknown starting dose Assume 30 units/day Assume 50 units/day units/hour Calculate daily dose e.g = 60 units/day units/hour Calculate daily dose e.g. Humalog Humulin N = 100 units/day units/hour Estimate based on weight (kg) Type 1 kg x 0.3 units/kg/day Type 2 kg x 0.5 units/kg/day e.g. 60 kg woman Type 1 18 units/day e.g. 100 kg man Type 2 50 units/day units/hour 0.8 units/hour

34 Start infusion at 1 unit/hr = 10 cc/hr Capillary blood glucose check q1h Basal rate May not be feasible in all settings C Yu Jan 2012

35 IV insulin infusion Check for institution s pre-printed order set 1. Order insulin concentration 50 units of Humulin R in 500cc D5W 1 unit = 10 cc 2. Order IV fluids Glucose containing (D5W, ⅔:⅓) 3. Calculate basal rate 4. Calculate correction factor

36 IV insulin infusion Check for institution s pre-printed order set 1. Order insulin concentration 50 units of Humulin R in 500cc D5W 1 unit = 10 cc 2. Order IV fluids Glucose containing (D5W, ⅔:⅓) 3. Calculate basal rate 4. Calculate correction factor Basal coverage Correction factor

37 Correction factor 1 unit of insulin will lower BG by mmol/l = 100/TDD e.g. 70M home insulin regimen Humulin 30/ TDD = units

38 Correction factor 1 unit of insulin will lower BG by mmol/l = 100/TDD e.g. 70M home insulin regimen Humulin 30/ TDD = 50 units CF = 100/TDD = 100/50 =

39 Correction factor 1 unit of insulin will lower BG by mmol/l = 100/TDD e.g. 70M home insulin regimen Humulin 30/ TDD = 50 units CF = 100/TDD = 100/50 = 2 1 unit of insulin will lower BG by 2 mmol/l

40 Correction factor 1 unit of insulin will lower BG by mmol/l = 100/TDD e.g. 60 F home insulin regimen Humulin 30/70 Humalog Glargine 14 hs TDD = units CF = 100/TDD = 100/ = 1 unit of insulin will lower BG by mmol/l

41 Correction factor 1 unit of insulin will lower BG by mmol/l = 100/TDD e.g. 60 F home insulin regimen Humulin 30/70 Humalog Glargine 14 hs TDD = 33 units CF = 100/TDD = 100/33 = 3 1 unit of insulin will lower BG by 3 mmol/l

42 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 50 then CF =

43 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 50 then CF = 2 then 6+2=

44 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 50 then CF = 2 then 6+2=8 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

45 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 33 then CF = then 6+ =

46 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 33 then CF = 3 then 6+3=9 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

47 Start infusion at 1 unit/hr = 10 cc/hr Basal rate Capillary blood glucose check q1h May not be feasible If BG: Give additional bolus of: in all settings <4.0 Give ½ amp D5W, check BG in 15 min, call MD Continue at current rate unit = 10 cc and continue at current rate unit = 20 cc and continue at current rate Correction factor unit = 30 cc and continue at current rate unit = 40 cc and continue at current rate > unit = 50 cc, call MD If additional bolus required for 2 consecutive hours, increase infusion rate by 0.5 u/hr = 5 cc/hr May need to adjust If no additional bolus required for 2 consecutive hours, decrease capillary blood glucose check to q4h C Yu Jan 2012

48 The Surgery Procedure Timing Plan to eat

49 The Surgery Procedure Procedure Major cardiovascular Likely post-op ICU Day surgery OR <2 hours DM regimen IV insulin drip IV insulin drip Ensure basal coverage until eating Ensure basal coverage until eating Timing Plan to eat

50 The Surgery Procedure Timing Timing Morning case Afternoon Unknown DM regimen Ensure adequate basal Adequate basal or IV insulin drip Plan to eat

51 The Surgery Procedure Timing Plan to eat Plan to eat Same day POD1 POD2 or later DM regimen Resume pre-op regimen once eating Ensure adequate basal Adequate basal or IV insulin drip

52 Outline Background and evidence Approach to the perioperative patient with DM The patient The treatment The surgery Case discussions

53 Case #1 52F scheduled for TAH tomorrow am DM2 x 6 years, obesity Medications Metformin 1000mg bid Gliclazide MR 60mg am Humulin N 20u hs Atorvastatin 10mg hs Perindopril 8mg

54 The Patient Type 1 or Type 2 Type 1 need insulin at all times!!! Glycemic control A1c, SMBG Diet NPO, DAT, clear fluids, NG feeds, TPN Activity level Medications Steroids Organ dysfunction/failure Ischemia Type 2 A1c 7.8%

55 The Treatment Oral agents Insulin Both Metformin Gliclazide Humulin N

56 Oral anti-hyperglycemic drugs Class Agents Concern Stop if: Biguinides Metformin Lactic acidosis CHF, renal insufficiency (egfr <30ml/min), hypoperfusion, or chronic pulmonary disease, at risk of developing renal failure and lactic acidosis, iv contrast dye Sulfonylurea Gliclazide (Diamicron) Glyburide (Diabeta) Glimeperide (Amaryl) Repaglinide (Gluconorm) Nataglinide (Starlix) Hypoglycemia (Elderly, impaired renal function, poor nutritional intake Hypoglycemia NPO, reduce dose if diet reduced NPO

57 The Surgery Procedure Timing Plan to eat

58 Write orders Basal coverage Correction factor

59 Ensuring basal coverage Usual DM regimen Oral agents only Oral agents + bedtime N Oral agents + bedtime Lantus or Levemir Mixed insulin BID MDI with bedtime N MDI with am and bedtime N MDI with Lantus or Levemir Insulin pump Basal coverage for AM of surgery Hold until eating Usual dose of bedtime N Usual dose of bedtime Lantus or Levemir 20% of TDD as morning N Usual dose of bedtime N 70% of am N Continue usual dose Continue basal rate

60 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 50 then CF = 2 then 6+2=8 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

61 Case #2 29M MVC multiple fractures and head injury Type 1 DM since age 4 Medications Humalog Lantus 12 units hs On call to OR

62 The Patient Type 1 or Type 2 Type 1 need insulin at all times!!! Glycemic control A1c, SMBG Diet NPO, DAT, clear fluids, NG feeds, TPN Activity level Medications Steroids Organ dysfunction/failure Ischemia Type 1 A1c 8.5% Sedentary post #

63 The Treatment Oral agents Insulin Both Humalog Lantus 12 hs

64 The Surgery Procedure Timing Plan to eat

65 Write orders Basal coverage Correction factor

66 Ensuring basal coverage Usual DM regimen Oral agents only Oral agents + bedtime N Oral agents + bedtime Lantus or Levemir Mixed insulin BID MDI with bedtime N MDI with am and bedtime N MDI with Lantus or Levemir Insulin pump Basal coverage for AM of surgery Hold until eating Usual dose of bedtime N Usual dose of bedtime Lantus or Levemir 20% of TDD as morning N Usual dose of bedtime N 70% of am N Continue usual dose of Lantus or Levemir Continue basal rate Continue Lantus 12 units hs

67 Basal insulin = 40% TDD Home regimen TDD Basal (40% TDD) MDI Calculate daily dose e.g. Humalog Lantus = 31 units/day 31 x 0.40 = 12 Either calculate basal from TDD or use Lantus dose = 12 units/day Insulin drip rate = basal rate/24 hours 12 units/24 hours = 0.5 units/hour

68 Correction factor (100/TDD) Target a BG of 6 mmol/l Start at 6+CF e.g. if TDD = 33 then CF = 3 then 6+3=9 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

69 Case #3 75M POD2 bowel resection Type 2 DM x 10 years Medications at home Metformin 1000mg bid Gliclazide MR 120mg Sitagliptin 100mg

70 Case #3 75M POD2 bowel obstruction Type 2 DM x 10 years A1c 7.6% Medications at home Metformin 1000mg bid Gliclazide MR 120mg Sitagliptin 100mg Poor appetite post-op only minimal clear fluids Blood sugars mmol/l Baseline egfr >60ml/min Cr 95 Postop Cr 150

71 Case #3 Restart metformin + sitagliptin Restart metformin + gliclazide + sitagliptin Start sliding scale Start IV insulin drip Start basal insulin Start basal insulin + correction factor

72 Oral anti-hyperglycemic drugs Class Agents Concern Stop if: Biguinides Metformin Lactic acidosis CHF, renal insufficiency (egfr <30ml/min), hypoperfusion, or chronic pulmonary disease, at risk of developing renal failure and lactic acidosis, iv contrast dye Sulfonylurea Gliclazide (Diamicron) Glyburide (Diabeta) Glimeperide (Amaryl) Repaglinide (Gluconorm) Nataglinide (Starlix) Hypoglycemia (Elderly, impaired renal function, poor nutritional intake Hypoglycemia NPO, reduce dose if diet reduced NPO

73 Oral anti-hyperglycemic drugs Class Agents Concern Stop if: DPPIV Inhibitors Thiazolidine diones (TZD) Alphaglucosidase inhibitor Sitagliptin (Januvia) Saxagliptin (Onglyza) Linagliptin (Trajenta ) Pioglitazone (Actos) Rosiglitazone (Avandia) Renal impairment: Sita egfr <50 Saxa 2.5mg if egrf Lina approved in ESRD Causes CHF Rosi increased CV mortality Bladder CA Atypical fractures NPO CHF CAD Liver failure Acarbose GI upset NPO

74 Basal insulin = 40% TDD Home regimen TDD Basal (40% TDD) Oral agents only Assume 30 units/day 12 Oral agents + bedtime insulin Mixed insulin BID MDI Unknown starting dose Assume 50 units/day Calculate daily dose e.g = units/day Calculate daily dose e.g. Humalog Humulin N = units/day Estimate based on weight (kg) Type 1 kg x 0.3 units/kg/day Type 2 kg x 0.5 units/kg/day e.g. 60 kg woman Type 1 units/day e.g. 100 kg man Type 2 units/day

75 Write orders Basal coverage Correction factor

76 Basal insulin 12 units/day Humulin Novolin Sanofi Onset (h) Peak (h) Duration (h) BASAL N - - NPH Levemir Lantus Subcutaneous N/NPH 40% AM 60% HS 25% q6h 33% q8h Levemir/Lantus 100% HS Intravenous drip 5 units AM 7 units HS 3 units q6h 4 units q8h 12 units hs 0.5 units/hour

77 Case #3 Humulin N 5 units AM 7 units HS Humalog correction factor 100/TDD 100/30 = 3 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

78 Case #3 Breakfast Lunch Dinner Bedtime Blood sugar Humulin N Humalog Correction Required 5 units of Humalog correction Can increase basal insulin by 4 units Humulin N 7 units AM 9 units HS

79 Case #3 Once eating: If Cr back at baseline Restart oral medications If Cr remains high Add Bolus insulin

80 Case #4 58F scheduled for total thyroidectomy for multinodular goitre Type 2 DM for 10 years A1c 7.3% Metformin 1g bid Humulin Mix

81 Write orders Basal coverage Correction factor

82 Ensuring basal coverage Usual DM regimen Oral agents only Oral agents + bedtime N Oral agents + bedtime Lantus or Levemir Mixed insulin BID MDI with bedtime N MDI with am and bedtime N MDI with Lantus or Levemir Insulin pump Basal coverage for AM of surgery Hold until eating Usual dose of bedtime N Usual dose of bedtime Lantus or Levemir 20% of TDD as morning N Usual dose of bedtime N 70% of am N Continue usual dose Continue basal rate e.g. Humalog Mix TDD = units/day 20% TDD = units N in am

83 Ensuring basal coverage Usual DM regimen Oral agents only Oral agents + bedtime N Oral agents + bedtime Lantus or Levemir Mixed insulin BID MDI with bedtime N MDI with am and bedtime N MDI with Lantus or Levemir Insulin pump Basal coverage for AM of surgery Hold until eating Usual dose of bedtime N Usual dose of bedtime Lantus or Levemir 20% of TDD as morning N Usual dose of bedtime N 70% of am N Continue usual dose Continue basal rate e.g. Humalog Mix TDD = 100 units/day 20% TDD = 20 units N in am

84 Correction factor (100/TDD) TDD = 100 then CF = 1 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

85 Case #5 78M POD 5 hip fracture ORIF Type 2 diabetes Metformin 1000mg BID Glyburide 10mg BID Continuous NG feeds - swallowing concerns BS on oral meds mmol/l

86 Write orders Basal coverage Correction factor

87 Case #5 Start correction factor estimate TDD of 30 units CF = 3 Blood glucose (mmol/l) Rapid insulin correction (units) None > and call MD

88 Case #5 06:00 12:00 18:00 00:00 Blood sugar Metformin + Glyburide Humalog Correction Required 11 units of Humalog correction/day Can start basal insulin Humulin N OR Increase CF to 1:2

89 Outline Background and evidence Approach to the perioperative patient with DM The patient The treatment The surgery Case discussions

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic

More information

DM Management in Elderly- What are the glucose targets?

DM Management in Elderly- What are the glucose targets? DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures

More information

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between

More information

Approximate Cost Reference List i for Antihyperglycemic Agents

Approximate Cost Reference List i for Antihyperglycemic Agents Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4

More information

Intensive Insulin Therapy in Diabetes Management

Intensive Insulin Therapy in Diabetes Management Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition

More information

Kaiser Sunnyside Medical Center Inpatient Pharmacy Manual

Kaiser Sunnyside Medical Center Inpatient Pharmacy Manual Page: 1 of 10 PURPOSE To provide a standard procedure for optimizing care of the inpatient with hyperglycemia and/or diabetes. Substantially provide safe and effective glucose control for all adult inpatients.

More information

INSULIN INTENSIFICATION: Taking Care to the Next Level

INSULIN INTENSIFICATION: Taking Care to the Next Level INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely

More information

(30251) Insulin SQ Prandial Carbohydrate

(30251) Insulin SQ Prandial Carbohydrate Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered

More information

Inpatient Treatment of Diabetes

Inpatient Treatment of Diabetes Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient

More information

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl

More information

10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama

10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University

More information

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding

More information

BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS

BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,

More information

FYI: (Acceptable range for blood glucose usually 70-110 mg/dl. know your institutions policy.)

FYI: (Acceptable range for blood glucose usually 70-110 mg/dl. know your institutions policy.) How Insulin Works: Each type of insulin has an onset, a peak, and a duration time. Onset is the length of time before insulin reaches the bloodstream and begins lowering blood Peak is the time during which

More information

How To Treat Diabetes

How To Treat Diabetes Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in

More information

A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration

A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast

More information

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin

More information

Britni Hebert, MD PGY-1

Britni Hebert, MD PGY-1 Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,

More information

Implementing The Portland Protocol - Continuous Intravenous Insulin Infusion in your institution

Implementing The Portland Protocol - Continuous Intravenous Insulin Infusion in your institution Implementing The Portland Protocol - Continuous Intravenous Insulin Infusion in your institution Anthony P. Furnary, MD St Vincent Medical Center Providence Health Systems Portland, OR Phased Implementation

More information

There seem to be inconsistencies regarding diabetic management in

There seem to be inconsistencies regarding diabetic management in Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional

More information

Managing the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS

Managing the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS Managing the Hospitalized Patient on Insulin: Care Transition Catie Prinzing MSN, APRN, CNS Diabetes and Hospitalization People with DM are hospitalized 3x more frequently than patients without diabetes

More information

Clinical Guideline Diabetes management during surgery (adults)

Clinical Guideline Diabetes management during surgery (adults) Clinical Guideline Diabetes management during surgery (adults) Standard 8 of the National Service Framework for Diabetes states that all children, young people and adults with diabetes admitted to hospital,

More information

Insulin Initiation and Intensification

Insulin Initiation and Intensification Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics

More information

Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above

Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random

More information

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah

More information

Antidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.

Antidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production

More information

Treatment of Type 2 Diabetes

Treatment of Type 2 Diabetes Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored

More information

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common

More information

Antihyperglycemic Agents Comparison Chart

Antihyperglycemic Agents Comparison Chart Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion

More information

Diabetes: Medications

Diabetes: Medications Diabetes: Medications Presented by: APS Healthcare Southwestern PA Health Care Quality Unit (APS HCQU) May 2008 sh Disclaimer Information or education provided by the HCQU is not intended to replace medical

More information

Ten Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014

Ten Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014 Ten Ways to Prevent Insulin-Use Errors in Your Hospital ASHP Research and Education Foundation May 14, 2014 To Ask Questions and Adjust the Control Panel Expand or Collapse Type your question here Faculty

More information

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1) Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the

More information

Information for Patients

Information for Patients Information for Patients Guidance for Diabetic Persons having bowel preparation for a flexible sigmoidoscopy or a colonoscopy or a combined gastroscopy and colonoscopy This guidance is provided to assist

More information

CARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy

CARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy Page 1 of 5 INDICATIONS EXCLUSIONS 2 consecutive blood glucose measurements greater than 110 mg per dl AND NPO with a continuous caloric source AND Diagnosis of : Cardio-thoracic Surgery NOTE: This protocol

More information

Surgery and Procedures in Patients with Diabetes

Surgery and Procedures in Patients with Diabetes Surgery and Procedures in Patients with Diabetes University Hospitals of Leicester NHS Trust DEFINITIONS Minor Surgery and Procedures: expected to be awake, eating and drinking by the next meal, total

More information

Type 2 Diabetes Medicines: What You Need to Know

Type 2 Diabetes Medicines: What You Need to Know Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral

More information

Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner

Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers

More information

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2 Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick

More information

Presented By: Dr. Nadira Husein

Presented By: Dr. Nadira Husein Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,

More information

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth

More information

When and how to start insulin: strategies for success in type 2 diabetes

When and how to start insulin: strategies for success in type 2 diabetes 1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology

More information

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย

More information

A patient s guide to the. management of diabetes at the time of surgery

A patient s guide to the. management of diabetes at the time of surgery A patient s guide to the management of diabetes at the time of surgery Diabetes is a common condition, affecting at least 4 to 5% of people in the UK. At least 10% of patients undergoing surgery have diabetes.

More information

Diabetes: When To Treat With Insulin and Treatment Goals

Diabetes: When To Treat With Insulin and Treatment Goals Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy

More information

Endocrine Disorders. Diabetes Meds Objectives. Diabetes Type 1 and Type 2. Insulin Dynamics. Insulin is all about timing! Rapid acting insulin O P D

Endocrine Disorders. Diabetes Meds Objectives. Diabetes Type 1 and Type 2. Insulin Dynamics. Insulin is all about timing! Rapid acting insulin O P D Endocrine Disorders Diabetes Meds Objectives Explain the action of the various types of insulin currently available Identify the relationship between insulin peak and risk for hypoglycemia Discuss rationale

More information

Algorithms for Glycemic Management of Type 2 Diabetes

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

New Non-Insulin Therapies for Type 2 Diabetes Mellitus

New Non-Insulin Therapies for Type 2 Diabetes Mellitus New Non-Insulin Therapies for Type 2 Diabetes Mellitus Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada Disclosure Relationships

More information

Fundamentals of Diabetes Care Module 5, Lesson 1

Fundamentals of Diabetes Care Module 5, Lesson 1 Module 5, Lesson 1 Fundamentals of Diabetes Care Module 5: Taking Medications Healthy Eating Being Active Monitoring Taking Medication Problem Solving Healthy Coping Reducing Risks Foundations For Control

More information

Diabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)

Diabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult) Review Due Date: 2016 May PATIENT CARE ORDERS Weight (kg) Known Adverse Reactions or Intolerances DRUG No Yes (list) FOOD No Yes (list) LATEX No Yes ***See Suggestions for Management (on reverse)*** ***If

More information

Medicines Used to Treat Type 2 Diabetes

Medicines Used to Treat Type 2 Diabetes Goodman Diabetes Service Medicines Used to Treat Type 2 Diabetes People who have type 2 diabetes may need to take medicine to help lower their blood glucose, in addition to being active & choosing healthy

More information

Diabetes Fundamentals

Diabetes Fundamentals Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence

More information

Pills for Type 2 Diabetes. A Guide for Adults

Pills for Type 2 Diabetes. A Guide for Adults Pills for Type 2 Diabetes A Guide for Adults December 2007 Fast Facts on Diabetes Pills n Different kinds of diabetes pills work in different ways to control blood sugar (blood glucose). n All the diabetes

More information

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word

More information

Managing the U Managing the U--500 500 Patient as a Surg as a Sur ical Inpatient

Managing the U Managing the U--500 500 Patient as a Surg as a Sur ical Inpatient Managing the U-500 Patient as a Surgical Inpatient Tyler Fischback Pharmacy Specialist St. Clare Hospital I have no conflicts of interest to disclose The Case DM is a 37 y.o.. developmentally delayed T2DM

More information

Diabetes Medications. Minal Patel, PharmD, BCPS

Diabetes Medications. Minal Patel, PharmD, BCPS Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore

More information

Diabetes Treatments: Options for Insulin Delivery. Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute

Diabetes Treatments: Options for Insulin Delivery. Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Diabetes Treatments: Options for Insulin Delivery Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Diabetes 21 million people in the U.S. have diabetes $132 billion each

More information

Medicines for Type 2 Diabetes A Review of the Research for Adults

Medicines for Type 2 Diabetes A Review of the Research for Adults Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high

More information

TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.

TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic. TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent

More information

Quick Reference Guide

Quick Reference Guide 2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING

More information

Type 1 and Type 2 Diabetes in Pediatric Practice

Type 1 and Type 2 Diabetes in Pediatric Practice Type 1 and Type 2 Diabetes in Pediatric Practice Chirag R. Kapadia, MD Division of Endocrinology, Phoenix Children s Hospital Clinical Assistant Professor, U of A College of Medicine Presentation outline

More information

Insulin/Diabetes Calculations

Insulin/Diabetes Calculations Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate

More information

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each

More information

DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS

DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used

More information

User guide Basal-bolus Insulin Dosing Chart: Adult

User guide Basal-bolus Insulin Dosing Chart: Adult Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For

More information

Guidelines for Type 2 Diabetes Diagnosis

Guidelines for Type 2 Diabetes Diagnosis Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose

More information

Cardiac Rehabilitation New Brunswick: Tutorial Series. Diabetes Mellitus Overview, pharmacotherapy and exercise considerations

Cardiac Rehabilitation New Brunswick: Tutorial Series. Diabetes Mellitus Overview, pharmacotherapy and exercise considerations Cardiac Rehabilitation New Brunswick: Tutorial Series Diabetes Mellitus Overview, pharmacotherapy and exercise considerations Overview Prevalence of diabetes Definition and Diagnosis Risk factors and complications

More information

Diabetes: Beyond the D50. Leslie Huntington, BS, Paramedic Mobile Training Unit Oregon OHA-EMS and Trauma Systems

Diabetes: Beyond the D50. Leslie Huntington, BS, Paramedic Mobile Training Unit Oregon OHA-EMS and Trauma Systems Diabetes: Beyond the D50 Leslie Huntington, BS, Paramedic Mobile Training Unit Oregon OHA-EMS and Trauma Systems The EMS View of Diabetes Management BG low? Give some form of sugar. Hero! BG somewhere

More information

SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS

SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS PURPOSE To establish a process that will enable Certified Diabetes Educators (CDE) and/or staff with Board Certification in Advanced Diabetes Management

More information

SECTION: NM NUMBER: 20. HENRY FORD HOSPITAL DETROIT, MICHIGAN TITLE: GLYCEMIC CONTROL INTENSIVE CARE PROTOCOL UNIT: All ICUs

SECTION: NM NUMBER: 20. HENRY FORD HOSPITAL DETROIT, MICHIGAN TITLE: GLYCEMIC CONTROL INTENSIVE CARE PROTOCOL UNIT: All ICUs CLINICALPROTOCOL MULTIDISCIPLINARY SECTION: NM NUMBER: 2 HENRY FORD HOSPITAL DETROIT, MICHIGAN TITLE: GLYCEMIC CONTROL INTENSIVE CARE PROTOCOL UNIT: All ICUs APPROVED: 3/3 REVIEWED: REVISED: 12/3, 5/,

More information

Glucose Management University of Colorado Hospital

Glucose Management University of Colorado Hospital Glucose Management University of Colorado Hospital Bridget Everhart, MSN, NP, CDE Inpatient Diabetes Educator Bridget.Everhart@uch.edu M F Pager 303 266-7898 UCH Diabetes Program Michael McDermott MD Diabetes

More information

Onset Peak Duration Comments

Onset Peak Duration Comments Rapid- Acting 5-15 minutes 0.5-3 hours 3-5 hours Meal should be available before administering, ideally taking within 10 minutes of eating). Good in refrigerator (36-46 F) until expiration date. Protect

More information

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of

More information

Medications for Type 2 Diabetes

Medications for Type 2 Diabetes Main Page Risk Factors Symptoms Diagnosis Treatment Screening Complications Reducing Your Risk Talking to Your Doctor Living With Type 2 Diabetes Resource Guide Medications for Type 2 Diabetes by Karen

More information

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type

More information

Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR

Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*

More information

Pharmaceutical Management of Diabetes Mellitus

Pharmaceutical Management of Diabetes Mellitus 1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal

More information

Let s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014

Let s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014 Let s Talk About Meters and Meds Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014 How to monitor diabetes control: Hemoglobin A 1 C, or just A 1

More information

Transitions: MNT for Basic Diabetes Medications to Complex Insulin Regimens. Sara Weigel RDN, LD, CDE MAND Annual Meeting May 1 st 2015

Transitions: MNT for Basic Diabetes Medications to Complex Insulin Regimens. Sara Weigel RDN, LD, CDE MAND Annual Meeting May 1 st 2015 Transitions: MNT for Basic Diabetes Medications to Complex Insulin Regimens Sara Weigel RDN, LD, CDE MAND Annual Meeting May 1 st 2015 Objectives 1) Describe and discuss some of the most common diabetes

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow

More information

Diabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.

Diabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph. Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact

More information

Intensifying Insulin Therapy

Intensifying Insulin Therapy Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning

More information

ONCE ONLY GLUCAGON and Fast Acting Glucose gel (PGD) For nurse administration under Patient Group Direction (Trust wide PGD in place)

ONCE ONLY GLUCAGON and Fast Acting Glucose gel (PGD) For nurse administration under Patient Group Direction (Trust wide PGD in place) ADULT INSULIN PRERIPTION AND BLOOD GLUCOSE MONITORING CHART Ward CONSULTANT DATE OF ADMISSION Please affix Patient s label here Ward Ward.../...year PATIENT NAME....... DATE OF BIRTH... NHS NUMBER.......

More information

TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS. Friday, August 16, 13

TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS. Friday, August 16, 13 TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS 1 Heather Healy, FNP-BC Martha Shelver, CS, ACNP-BC Saint Alphonsus Regional Medical Center 2 OBJECTIVES 3 Review the current management algorithms

More information

Workshop A Tara Kadis

Workshop A Tara Kadis Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system

More information

Management of Clients with Diabetes Mellitus

Management of Clients with Diabetes Mellitus Management of Clients with Diabetes Mellitus Black, J.M. & Hawks, J.H. (2005) Chapters 47, (pp 1243-1288) 1288) Baptist Health School of Nursing NSG 4037: Adult Nursing III Carole Mackey, MNSc,, RN, PNP

More information

Individualizing Diabetes Care for Long Term Care Residents: A Guidebook. Practical information for diabetes management in Long Term care settings

Individualizing Diabetes Care for Long Term Care Residents: A Guidebook. Practical information for diabetes management in Long Term care settings Individualizing Diabetes Care for Long Term Care Residents: A Guidebook Practical information for diabetes management in Long Term care settings Created by: Long Term Care Working Group Of Health Care

More information

Peri-Operative Guidelines for Management of Diabetes Patients

Peri-Operative Guidelines for Management of Diabetes Patients Peri-Operative Guidelines for Management of Diabetes Patients Target blood glucose 6-10 mmol/l for all patients Acceptable blood glucose 4-11 mmol/l for all patients Definitions Non-Insulin Glucose Lowering

More information

In-hospital management of diabetes

In-hospital management of diabetes Dr. Tom Elliott MBBS, FRCPC Medical Direct 4102 2775 Laurel St. phone: 604.675.2491 Vancouver, BC fax: 604.875.5931 V5Z 1M9 Canada email: info@bcdiabetes.ca In-hospital management of diabetes General Management

More information

Case Studies: Initiation and Optimization of Insulin Therapy. Martha Nolte Kennedy, MD UCSF March, 2009

Case Studies: Initiation and Optimization of Insulin Therapy. Martha Nolte Kennedy, MD UCSF March, 2009 Case Studies: Initiation and Optimization of Insulin Therapy Martha Nolte Kennedy, MD UCSF March, 2009 When to Start Insulin? Insulinopenia: DM1, LADA, DM2 failed other medications, s/p Pancreatectomy,

More information

Insulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?

Insulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How? Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo

More information

Management of Diabetes: A Primary Care Perspective. Presentation Outline

Management of Diabetes: A Primary Care Perspective. Presentation Outline Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline

More information

Reducing the risk of patient harm: A focus on insulin

Reducing the risk of patient harm: A focus on insulin Reducing the risk of patient harm: A focus on insulin New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 1 Disclosure Matt Fricker, Matt Grissinger,

More information

Primary Care Type 2 Diabetes Update

Primary Care Type 2 Diabetes Update Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological

More information

Anti-Diabetic Agents. Chapter. Charles Ruchalski, PharmD, BCPS. Drug Class: Biguanides. Introduction. Metformin

Anti-Diabetic Agents. Chapter. Charles Ruchalski, PharmD, BCPS. Drug Class: Biguanides. Introduction. Metformin Chapter Anti-Diabetic Agents 2 Charles Ruchalski, PharmD, BCPS Drug Class: Biguanides The biguanide metformin is the drug of choice as initial therapy for a newly diagnosed patient with type 2 diabetes

More information

ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH.

ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH. ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH. ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO

More information

Medications for Diabetes

Medications for Diabetes AGS Diab Med Brochure 4/18/03 3:43 PM Page 1 Medications for Diabetes An Older Adult s Guide to Safe Use of Diabetes Medications THE AGS FOUNDATION FOR HEALTH IN AGING AGS Diab Med Brochure 4/18/03 3:43

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

Starting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres

Starting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier

More information

Saxagliptin (Onglyza) for type 2 diabetes

Saxagliptin (Onglyza) for type 2 diabetes Saxagliptin (Onglyza) for type 2 diabetes This Medicine Update is for people who are taking, or thinking about taking, saxagliptin. Summary Saxagliptin (brand name Onglyza) is a tablet that can be used

More information

Intensifying Insulin In Type 2 Diabetes

Intensifying Insulin In Type 2 Diabetes Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant

More information